Scenic: targeting genetic modifiers to suppress disease drivers
Emerging Company Profile: Amsterdam-based Scenic is developing small molecules against genetic modifiers for metabolic and inflammatory rare diseases, cancer
Scenic Biotech is building a compendium of genetic data to identify rare, naturally occurring genetic modifiers that suppress disease pathology despite the presence of disease-causing mutations.
Many rare diseases are driven by an underlying genetic mutation. But across nearly all of these patient populations, there is a small subset of patients that have no disease traits because they have a genetic modifier — a second rare genetic mutation that prevents the phenotypic expression of that disease. ...